Replies to post #157219 on Biotech Values

[DewDiligence]

AMRN—I don’t have a strong opinion one way or the other on the FDA’s granting NCE status; however, I’ve posted on this board that I don’t think Vascepa’s patents will stand up to P-IV challenges, which is why the NCE decision is so consequential.

[biomaven0]

Correction to my previous post - I wrote "Vescapa" instead of "Lovaza."

Should be:

Further, with Lovaza patent expiration not that far off, I just don't see insurers paying for AMRN's drug without the patient having first tried Lovaza.

Peter

[mcbio]

I've been consistently skeptical of AMRN, and I remain so today. I don't think they will get NCE status, and without it they won't get a partner. Further, with Vescapa patent expiration not that far off, I just don't see insurers paying for AMRN's drug without the patient having first tried Vescapa. Finally, with good reason, doctors are increasingly skeptical of biomarker-based results in the cardiac space - they want to see outcomes studies.

I'm with you on this. Combine those points with fact that AMRN has a ~$1.25B market cap and is a one-trick pony and I'd be pretty nervous if I were long (I'm not and never will be).

[Rawnoc]

Amarin's Vascepa: 5 Myths Debunked

http://seekingalpha.com/article/1220961-amarin-s-vascepa-5-myths-debunked